Rein Therapeutics Amends 10-K to Disclose Prior $2.58M Private Placement and Executive Compensation

summarizeSummary

Rein Therapeutics filed an amended 10-K to include omitted Part III information, revealing a $2.58 million private placement from April 2025 and detailing executive compensation and significant potential equity dilution.

check_boxKey Events

• Amended Annual Report Filed

  Rein Therapeutics filed a 10-K/A to amend its Annual Report on Form 10-K from March 26, 2026, adding previously omitted Part III information, including corporate governance, executive compensation, and related party transactions.

• Prior $2.58M Private Placement Disclosed

  The company disclosed an April 2025 private placement where it raised approximately $2.58 million through the issuance of pre-funded warrants to purchase 1,613,195 shares at an effective price of $1.599 per share. Bios Partners, a significant shareholder, participated in this financing.

• Executive Compensation Details for 2025

  The filing provided executive compensation for 2025, including CEO Brian Windsor's salary of $575,000, a bonus of $287,500, and option awards valued at $20,195. Interim CFO Timothy Cunningham received a salary of $433,940.

• Significant Potential Equity Dilution

  As of December 31, 2025, the company had 3,143,997 shares to be issued upon exercise of outstanding options and 1,921,694 shares remaining available for future issuance under equity compensation plans. If all these shares were issued, potential dilution would be approximately 18.06% based on 28,039,032 outstanding shares.

auto_awesomeAnalysis

This 10-K/A filing amends the Annual Report on Form 10-K filed on March 26, 2026, primarily to include previously omitted Part III information concerning corporate governance, executive compensation, security ownership, and related party transactions. While an administrative update, it provides crucial details about the company's financial activities, particularly given its previously disclosed 'going concern' warning and critically short cash runway. The amendment reveals an April 2025 private placement where Rein Therapeutics raised approximately $2.58 million by issuing pre-funded warrants to purchase 1.61 million shares at $1.599 per share. This capital raise, though historical, was substantial for the company, representing a significant portion of its market capitalization at the time of the transaction. The participation of Bios Partners, a greater than 5% beneficial holder, highlights their continued involvement. Additionally, the filing details executive compensation for 2025 and indicates a potential future dilution of over 18% from outstanding options and shares available under equity compensation plans. This disclosure provides investors with a more complete picture of the company's financing strategy and compensation structure, which is vital for assessing its long-term viability amidst ongoing financial challenges.